Risk factors and treatment of pneumothorax secondary to granulomatosis with polyangiitis: a clinical analysis of 25 cases

Xuhua Shi, Yongfeng Zhang and Yuewu Lu*

Abstract

Objectives: To investigate the risk factors and treatment strategies for pneumothorax secondary to granulomatosis with polyangiitis (GPA).

Method: Retrospective analysis of cases with pneumothorax secondary to GPA from our own practice and published on literature.

Results: A total of 25 patients, 18 males and 7 females, mean age 44 ± 15.7 years, were analyzed. Diagnosis included pneumothorax (11 cases), hydropneumothorax (n = 5), empyema (n = 8) and hemopneumothorax (n = 1). 88% (22/25) patients showed single/multiple pulmonary/subpleural nodules with/without cavitation on chest imaging. Erythrocyte sedimentation rate and C-reactive protein were both elevated. Corticosteroids and immunosuppressive agents were used in 16 cases. Five cases received steroid pulse therapy, of which 4 patients survived. Pleural drainage was effective in some patients. Seven patients underwent surgical operations. In the 10 fatal cases, infection and respiratory failure were the most common cause. Lung biopsy/autopsy showed lung/pleural necrotizing granulomatous vasculitis, breaking into the chest cavity, pleural fibrosis, bronchial pleural fistula, etc. The mean age in the death group was greater than the survival group (53 ± 12.9 years vs 40.1 ± 14.7 years, p = 0.05), the ineffective pleural drainage was also higher in the death group (5/5 vs 0/7, p = 0.01).

Conclusions: Pneumothorax was seen in the active GPA, due to a variety of reasons, and gave rise to high fatality rate. Aggressive treatment of GPA can improve the prognosis. Older and lack of response for pleural drainage indicates poor prognosis.

Keywords: Granulomatosis with Polyangiitis, Wegener’s granulomatosis, Pneumothorax

Background

Granulomatosis with polyangiitis (GPA), also known as Wegener’s granulomatosis, is a necrotizing granulomatous vasculitis, most commonly involving lung (Fig. 1), upper respiratory tract, and kidney [1]. When the respiratory system is involved, lung imaging study usually shows nodules, infiltrates, alveolar hemorrhage [2]. When pleural is involved, the patient can present with pleurisy, pleural effusion and thickening. Pneumothorax is a rare but serious complication, when occurred, can be categorized into pneumothorax, hydropneumothorax, empyema, hemopneumothorax, etc [3, 4]. So far there were only 20 cases of pneumothorax reported and the clinical presentation varied. Also, the cause and risk factors of GPA associated pneumothorax are unclear, and there is no consensus on important aspects of treatment strategy, such as, when the pneumothorax or infection is developed, how should treatment for the primary disease be adjusted? How to appropriately apply the pleural drainage and other surgical interventions? We encountered one case of GPA associated hydropneumothorax in our clinic who recovered after undergone active treatment of the primary disease.
and pleural drainage. The incidence of GPA associated pneumothorax is low. However, if not treated properly the fatality rate can be quite high. Currently, there is still no cohort-based research. Therefore, we conducted a retrospective analysis of our case and all cases reported in the literature [4–24], aiming to identify the risk factors of GPA-associated pneumothorax and explore the important principles of its clinical management once occurred, to guide the optimal treatment of the patients.

**Materials and methods**

Because it is a retrospective research, the period of observation spans from 1978 (the first case) to 2015 (the last case). The patients came from two sources. The first was the case diagnosed and treated in our clinic. The second source included cases reported in the literature identified from the search of major databases, including: Chinese Biomedical Literature Database (CBM), Pubmed, EMBASE, and BIOSIS Preview. The searching key words were “pneumothorax,” “multi-vessel granulomatous inflammation” and “Wegener’s granulomatosis.” Full text articles were retrieved for review. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Given the small number of reported cases and wide time span covered by the search, we went over the papers carefully, excluded the cases of pneumothorax unrelated to GPA (for example, pneumothorax caused by lung biopsy during the disease diagnosis). One lung imaging study included 31 cases of Wegener’s granulomatosis confirmed by clinical and pathology examination, but only had 1 case complicated by pneumothorax. We carefully reviewed and collected information on each patient’s clinical diagnoses, gender, age, time from disease onset to the development of pneumothorax, diagnosis of pneumothorax, the type of pneumothorax (pneumothorax, hydropneumothorax, empyema, hemopneumothorax), clinical presentations, laboratory test results (including anti-neutrophil cytoplasmic antibodies, anti-PR3 antibody, erythrocyte sedimentation rate, C-reactive protein), lung imaging findings (X-ray / CT), corticosteroids and immunosuppressants treatment, pleural drainage, surgery, infection (infection site, pathogens, etc.), biopsy / autopsy pathology results. Four cases were reported from non-English literature, for which the information was gathered from the abstract written in English.

Case analysis included general patient characteristics (gender, age, duration of disease, type of pneumothorax, lung imaging findings, extrapulmonary manifestations, laboratory results, treatment and prognosis), infection (infection site, pathogens, etc.), biopsy / autopsy pathology results (lungs and other organs), as well as comparison between death and survived patients. This analysis included patients who met the 1990 American College of Rheumatology (ACR) classification criteria for Wegener’s granulomatosis [1, 25] defined as follows: 1) Nasal or oral inflammation: development of painful or painless oral ulcers or purulent or bloody nasal discharge; 2) Abnormal chest radiograph: chest radiograph showing the presence of nodules, fixed infiltrates, or cavities; 3) Urinary sediment: microhematuria (>5 red blood cells per high power field) or red cell casts in urine sediment; 4) Granulomatous inflammation on biopsy: histologic changes showing granulomatous inflammation within the wall of an artery or in the perivascular or extravascular area (artery or arteriole). Patients need to meet at least 2 criteria to be diagnosed as Wegener’s granulomatosis. The cases diagnosed before 1990 were confirmed with biopsy showing necrotizing granulomatous vasculitis.

**Statistical analysis**

The general characteristics of the patients were summarized with descriptive statistics. Age, duration, anti-PR3, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were expressed as mean ± standard deviation, and were compared between death group and survival group using independent t-test. Categorical variables, including sex, types of pneumothorax, chest imaging (nodules, cavity, pulmonary hemorrhage), extrapulmonary manifestations (fever, skin lesions, nasal and sinus involvement, oral ulcers, renal involvement, nervous system involvement, arthralgia / arthritis, parotid swelling), positive ANCA, pleural drainage, surgery, spontaneous absorption, death, infection site, pathogens, biopsy site and pathology,
therapy and interruption of treatment, risk factors for pneumothorax secondary to GPA, were summarized as percentage, and were analyzed between death group and survival group using chi-square test.

**Results**

The first case in the series was from our clinic. The patient had sinusitis for 20 years, purulent nasal discharge, hemoptysis for 3 years, repeated skin ulcers for 2 years, difficulty in breathing for 2 months before being hospitalized. At admission, lung CT showed bilateral multiple nodules with/without cavity (biopsy indicated granulomatous inflammation). Right cavity ruptured and resulted in hydropneumothorax. C-ANCA was positive, the level of anti-PR3 was 150.5RU/ml. The condition improved after pleural drainage and treatment with corticosteroids and cyclophosphamide, cyclosporine A. The rest of the series included 1 case from the Chinese Biomedical Literature Database, and 23 cases from PubMed, EMBASE, BIOSIS Preview databases. The total was 25 cases.

The average age of the case series was 44 years, with a male to female ratio of 2.6: 1. The disease duration ranged from 1 month to 18 years. In 8 patients GPA was diagnosed after the occurrence of pneumothorax. The type of pneumothorax included pneumothorax, hydropneumothorax, empyema, hemopneumothorax. Respiratory symptoms presented were cough (5 cases), chest tightness and shortness of breath (9 cases), dyspnea (10 cases), and hemoptysis (2 cases). The majority of patients (88%) showed single or multiple nodules with/without cavitation on lung imaging. Most patients were treated with glucocorticoid (steroid pulse therapy for some patients) and immunosuppressive agents. In certain patients the medications were interrupted after the diagnosis of pneumothorax / infection and resulted in two deaths. None of the patients in the survivors group stopped the medication. Also, in the survivor group, about one-third patients received corticosteroid pulse therapy, while this was only 10% in the death group. Some patients did not undergo pleural drainage and successfully recovered from spontaneous absorption.

The effects of pleural drainage were also mixed. Seven patients underwent surgeries, including pulmonary cavity resection, pulmonary lobectomy, and partial pleurectomy, etc. Four patients underwent surgery because the lung failed to re-expand or there were large persistent air volume leaks after pleural drainage and the details were not recorded properly. The fatality rate was high due to infection, respiratory failure, sepsis, respiratory arrest (Table 1). Infection involved the lungs, thoracic cavity, blood circulation, etc. Pseudomonas aeruginosa were frequently detected (Table 2). Biopsy/autopsy showed lung nodules, pleural necrotizing granulomatous vasculitis, breaking into the pleural cavity, pleural fibrosis, and bronchial pleural fistula (Table 3). The average age of death group was greater than the average age of survivor group (53 ± 12.9 years vs 40.1 ± 14.7 years, \( p = 0.05 \)). In the death group, lack of response to pleural drainage which refers to the failure of the lung to re-expand or large persistent air volume leaks, was more common than that in the survivors (5/5 vs 0/7, \( p = 0.01 \)) (Table 4).

### Table 1 General characteristics of patients with pneumothorax secondary to GPA

| Clinical features | Results |
|------------------|---------|
| Male/Female (case) | 18(72%)/7(28%) |
| Age(year) | 44 ± 15.7(16~70) |
| Duration (weeks) | 26 ± 51.0(0.83~216) |
| Pneumothorax type (case) | |
| Pneumothorax | 11(44%) |
| Hydropneumothorax | 5(20) |
| Emphyema | 8(32%) |
| Hemopneumothorax | 1(4%) |
| Chest Imaging(n) | |
| Nodules (Multi/Single) | 22(88%) |
| Cavity | 21(84%) |
| Pulmonary hemorrhage | 1(4%) |
| Extrapulmonary manifestations (n) | |
| Fever | 11(44%) |
| Skin lesions (purpura, gangrene, ulcers, etc.) | 7(28%) |
| Nasal and sinus involvement | 15(60%) |
| Oral ulcers | 5(20%) |
| Glomerulonephritis and other | 13(52%) |
| Nervous system (facial paralysis, mononeuropathy, etc.) | 6(24%) |
| Arthralgia/arthritis | 11(44%) |
| Parotid swelling | 2(8%) |
| Laboratory tests | |
| ANCA-positive(n) | 13/20(65%) |
| Anti-PR3(RU/ml) | 176 ± 145.3(26~411) |
| ESR (mm/h) | 92 ± 31.6(24~145) |
| CRP (mg/dl) | 20 ± 27.4(2.35 – 90) |
| Pleural drainage(n) | 16 |
| Surgery(n) | 7(28%) |
| Spontaneous absorption(n) | 4(16%) |
| Death | 10(40%) |

Note: ANCA, anti-neutrophil cytoplasmic antibodies; anti-PR3, anti-proteinase 3 antibody; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein. These cases with empyema showed a clear pneumothorax at chest X-ray or CT scan.
Discussion

The incidence of pneumothorax in patients with GPA is low. So far, there were only individual case reports in the literature. Our analysis is the first systematic review of these cases. The results showed that pneumothorax secondary to GPA may be caused by many factors, is associated with high risk of fatality. Older age and non-response to pleural drainage indicate poor prognosis, and effective treatment of primary disease is very important to improve the prognosis.

There are different opinions for the cause of pneumothorax. Our analysis showed GPA associated pneumothorax is a collective effect of multiple factors (Table 5), rather than a single cause. First, 88% of patients in the analysis had pulmonary nodules, more frequent than the reported 40–70% in the general GPA patients [26]. Also, 21 out of 22 patients with pulmonary nodules had cavity, well above the 49% identified in general GPA patients population, [3] suggesting that breaking into the pleural cavity from cavitary nodule may be the main reason for the occurrence of pneumothorax (Fig. 2), especially cavitary nodules close to the pleura [9, 13, 17, 18]. Secondly, this analysis found that positive microbial culture of sputum and pleural drainage are common, and the same pathogen may be identified from both tests (in our patient, Aspergillus niger was detected from both sputum and pleural fluid drainage samples). This suggests that the secondary infection in the nodule cavity may contribute to the occurrence of pneumothorax, especially empyema in GPA patients [7]. The secondary infection is associated with cavity formation, and use of corticosteroids and immunosuppressants [8] not only increases the risk of infection, but also delays the wound healing after lung biopsy, thus causes pneumothorax [4]. Thirdly, the results of lung pathological examination in 2 patients showed bronchial pleural fistula is a pathological feature for pneumothorax [5, 8]. In addition, the disease progression itself involving the pleura may be a potential factor in the development of pneumothorax [3, 16]. In this analysis pleural biopsy revealed necrotizing granulomas and vasculitis. Epstein DM has reported a pneumothorax patient who did not have pulmonary manifestations at the diagnosis, but showed multiple pulmonary nodules one year later, suggesting pneumothorax may be caused by the primary disease itself that involves the pleura, and the emergence of pneumothorax indicates the likelihood of pulmonary lesion in the future [6]. Many patients in this analysis also had extrapulmonary manifestations. Inflammatory markers such as ESR, CRP were significantly increased, suggesting many of them were at the active stage of vasculitis when pneumothorax occurred. In only 1 patient who was confirmed GPA 18 years ago through nasal biopsy, wedge resection of lung and pleura partial resection were performed after the diagnosis of pneumothorax. Pathology exam showed subpleural blister with significant fibrosis, pulmonary fibroelastosis, no sign of vasculitis, and the pneumothorax may be caused by fibrous tissue traction [19]. Therefore, there are a few reasons and risk factors for pneumothorax in GPA patients. Breaking of nodule into the pleural cavity is the most common cause. Pneumothorax may occur at any time during the disease progression, while the majority of patients were in the active stage when it occurred.

This analysis also showed the prognosis of GPA patients complicated with pneumothorax is poor, and the fatality rate could be 40%, much higher than the general GPA patients [27]. The average age of patients who later died was higher than the survivors. Severe/ recurrent infections, respiratory failure were among the common causes of death. Lung infections, pleural cavity infections,

### Table 2 Infection in patients with pneumothorax secondary to GPA

| The site of infection and pathogens | n = 20 |
|-----------------------------------|-------|
| Lung                              | 4 (20%) |
| Pleural                           | 9 (45%) |
| Blood                             | 3 (15%) |
| Parotid                           | 1 (5%)  |

| Pathogens                        |       |
|----------------------------------|-------|
| Pseudomonas aeruginosa           | 5 (25%) |
| Hemolytic streptococcus          | 2 (10%) |
| Proteus                          | 1 (5%) |
| Bacteroides fragilis             | 1 (5%) |
| Streptococcus faecalis           | 1 (5%) |
| Candida albicans                 | 1 (5%) |
| Aspergillus niger                | 1 (5%) |

Note: A total of 20 cases

### Table 3 Biopsy/autopsy results of patients with pneumothorax secondary to GPA

| Biopsy site and pathology                      | Cases (n, %) |
|-----------------------------------------------|--------------|
| Lung (12 cases)                                |              |
| Pulmonary nodules necrotizing granulomatous vasculitis | 6/12(50.0%) |
| Bronchial pleural fistula                     | 2/12(16.7%) |
| Pleural necrotizing granulomatous vasculitis   | 1/12(8.3%)  |
| Subpleural blister and fibrosis, pulmonary fibrosis and elastic tissue hyperplasia | 1/12(8.3%) |
| Nose (necrotizing granulomatous vasculitis)    | 8            |
| Skin (leukocytoclastic vasculitis)             | 2            |
| Parotid (necrotizing granulomatous vasculitis) | 1            |
| Oral (necrotizing granulomatous vasculitis)    | 1            |

Note: lung biopsy/autopsy in a total of 12 cases
blood infections are the most common forms of infection, and the most common pathogen is Pseudomonas aeruginosa. We also found, in certain patients the use of corticosteroids and immunosuppressive agents were interrupted or reduced after the development of pneumothorax/ infection with an intention to control the risk of infection [14]. However, this did not seem to improve the prognosis. We believe because most patients are in the active stage of vasculitis, the treatment for primary disease should be maintained and unnecessary interruption is not recommended [9]. Treatment of primary disease may increase the risk of infection. If infection is present, it is recommended that sensitive antibiotics be given besides the treatment of primary disease to improve the prognosis [17–19]. In addition, pleural drainage can remove pleural effusion and help lung recruitment, but our analysis showed that not all patients benefit from pleural drainage, especially in the death group where the procedure showed ineffective for all patients. Therefore, we speculate that lack of response to pleural drainage may be an indicator of poor prognosis. On the other hand, in some patients who did not undergo pleural drainage, pneumothorax was absorbed spontaneously after the treatment of primary disease. So, pleural drainage should be decided based on the situation of the patients. If the patient is in general good state and has no obvious respiratory symptoms, decreased oxygenation, pleural drainage may not be necessary [16]. If the patient's condition is urgent, chest tube should be promptly placed. For patients not responding to pleural drainage, thoracotomy should be performed [21]. Also, for patients complicated with pleural infection, adequate drainage is essential [20]. Otherwise, extubation

| Table 4 | Patients characteristics related to morality |
|---------|---------------------------------------------|
| Clinical features | Death group (n = 10) | Survival group (n = 12) | P value |
| Male/Female (n) | 7 (70.0%)/3 (30.0%) | 8 (80.0%)/4 (40.0%) | 1.000 |
| Age (years) | 53 ± 12.9 (33~70) | 40 ± 14.7 (25~70) | 0.050 |
| Duration (weeks) | 19 ± 24.8 (10~48) | 34 ± 69.2 (0.83~216) | 0.547 |
| Extrapulmonary manifestations (n) | | | |
| Fever | 3 (30.0%) | 7 (58.3%) | 0.231 |
| Skin lesions (purpura, gangrene, ulceration) | 3 (30.0%) | 3 (25.0%) | 1.000 |
| Ear (hearing loss, otitis media) | 2 (20.0%) | 4 (33.3%) | 0.646 |
| Nasal and sinus involvement | 5 (50.0%) | 7 (58.3%) | 1.000 |
| Oral ulceration | 4 (40.0%) | 1 (8.3%) | 0.135 |
| glomerulonephritis | 6 (60.0%) | 6 (50.0%) | 0.691 |
| Nervous system (facial paralysis, multiple mononeuropathy, etc.) | 3 (30.0%) | 1 (8.3%) | 0.293 |
| Arthralgia/arthritis | 4 (40.0%) | 4 (33.3%) | 1.000 |
| Parotid swelling and pain | 2 (20.0%) | 0 (0.0%) | 0.195 |
| ESR (mm/h) | 104 ± 26.7 | 82 ± 33.9 | 0.233 |
| Infection (n) | 6 (60.0%) | 3 (25.0%) | 0.192 |
| Corticosteroids and Immunosuppressants (n) | | | |
| Steroid pulse therapy | 1 (10.0%) | 4 (33.3%) | 0.323 |
| Treatment interruption | 2/4 (50.0%) | 0/8 (0.0%) | 0.091 |
| Non-response to Pleural drainage (n) | 5/5 (100%) | 0/7 (0.0%) | 0.010 |
| Surgery (n) | 2 (20.0%) | 5 (41.7%) | 0.381 |

Note: 3 cases without prognostic information, n = 22 cases; ESR, erythrocyte sedimentation rate

| Table 5 | Risk factors for pneumothorax secondary to GPA |
|---------|---------------------------------------------|
| Risk factors | N |
| Active stage of Granulomatous vasculitis | 19/20 (95.0%)a |
| Pulmonary nodules broke into the chest cavity | 15 |
| Pleural necrotizing granulomatous vasculitis | 1/12 (8.3%)b |
| Bronchial pleural fistula | 2/12 (16.7%)b |
| Lesions fibrosis with pleural cohesion | 1/12 (8.3%)b |
| Secondary infection in nodule cavity | 3 |
| Lesions fibrosis due to immunosuppressant | 1 |
| Delayed wound healing due to Glucocorticoid | 2 |
| Others | 1 |

aBased on symptoms, laboratory tests, pathology
bLung biopsy in 12 cases
should be considered to reduce the risk of infection. Due to the small sample size, it is still unclear whether there are differences between different thoracic surgical methods. The common purpose of different surgical methods is to achieve lung expansion and to repair persistent air leaks. Therefore, video-assisted thoracic surgery (VATS) is recommended in order to reduce the damage to the patient. Not all nodules require operative resection except in those with cavity inside and adjacent to pleural. Similarly, pleurodesis is not always necessary and should be determined according to the patient’s actual conditions. According to my own understanding and experience, lung expansion and cessation of air leaks after surgical/immunosuppressive therapy and the effective control of severe complications such as infection are most important factors for a better prognosis. Different surgical methods do not have significant impact on the prognosis.

In summary, pneumothorax secondary to GPA generally occurs during active phase of the disease, and is caused by a variety of reasons. Aggressive treatment of primary disease can improve the prognosis. Pleural drainage should be considered based on the condition of patients, and ineffective pleural drainage indicates poor prognosis. The incidence of pneumothorax secondary to GPA is low but the case fatality rate is high. Here we reported the first retrospective analysis of a large case series of GPA associated pneumothorax, provided a comprehensive review of the risk factors for pneumothorax, and analyzed the advantages and disadvantages of the main treatment approaches. We think the information can help clinicians identify high-risk patients for pneumothorax and make rational treatment decisions. Because this study was a retrospective analysis, limited to the number of cases reported in the literature, the results may not be generalizable to all GPA patients. Physicians should make decisions based on each patient’s condition.

**Conclusions**
Pneumothorax was seen in the active GPA, due to a variety of reasons, and gave rise to high fatality rate. Aggressive treatment of GPA can improve the prognosis. Older and lack of response for pleural drainage indicates poor prognosis.

**Abbreviations**
ACR: American College of Rheumatology; CBM: Chinese Biomedical Literature Database; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; GPA: Granulomatosis with polyangiitis

**Acknowledgements**
No.
Funding
No.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
YL contributed to experimental design, coordination and interpreted the data. XS analyzed results and drafted the manuscript. YZ collected data of research. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study was approved by the Ethics Committee of Chiao-yang Hospital Ethics committee, Capital Medical University. Consent to participate was obtained from the participant.

Consent for publication
Consent to publish from the participant.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 7 November 2017 Accepted: 5 January 2018
Published online: 15 January 2018

References
1. Lutalo PM, D’Cruz DP. Diagnosis and classification of granulomatosis with polyangiitis (aka Wegener’s granulomatosis). J Autoimmun. 2014;48:4994–8.
2. Abdou NI, Kullman GJ, Hoffman GS, Sharp GC, Specks U, McDonald T, Garrity J, Goeken JA, Allen NB. Wegener’s granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. J Rheumatol. 2002;29(2):309–16.
3. Cordier JF, Valeyré O, Guilevín L, Loire R, Brechot JM. Pulmonary Wegener’s granulomatosis. A clinical and imaging study of 77 cases. Chest. 1990;97(4):906–12.
4. Sezer I, Kocabas H, Melikoglu MA, Budak BS, Ozbudak IH, Butun B. Spontaneous pneumothorax in Wegener’s granulomatosis: a case report. Mod Rheumatol. 2008;18(1):76–80.
5. Maguire R, Fauci AS, Doppman JL, Wolff SM. Unusual radiographic features of Wegener’s granulomatosis. AJR Am J Roentgenol. 1978;130(2):233–8.
6. Epstein OM, Geffter WB, Miller WT, Gohel V, Bonavita JA. Spontaneous pneumothorax: an uncommon manifestation of Wegener granulomatosis. Radiology. 1980;135(2):327–8.
7. Jaspan T, Davison AM, Walker WC. Spontaneous pneumothorax in Wegener’s granulomatosis. Thorax. 1982;37(10):774–5.
8. Woffendinbutte BH, Weber RF, Kho GS. Pneumothorax: a rare complication of Wegener’s granulomatosis. Eur J Respir Dis. 1986;73(1):233–7.
9. Ogawa M, Azemoto R, Makino Y, Mori Y, Iida S, Wakashin M, Ohto M. Pneumothorax in a patient with Wegener’s granulomatosis during treatment with immunosuppressive agents. J Intern Med. 1991;229(2):189–92.
10. Zhiren Li XB, Zhen J. The rare pulmonary manifestations of Wegener’s granulomatosis(Report of 2 cases and literature review). Chinese Journal of Practical Internal Medicine. 1992;24:216–7.
11. Courthialac C, Aumaitre O, Andre M, Kemery JL, Janicot H, Glain L, Michel JL. Features of tomodensitometry in the development of pleuropulmonary lesions related to Wegener’s granulomatosis. Rev Med Interne. 1999;20(7):571–8.
12. Tsushima K, Tanaka H, Urasihata K, Ogawara H, Gono H, Takashi S, Tsukada A, Yamamoto H, Kaneki T, Yamaguchi S, et al. A case of limited Wegener granulomatosis with hypereosinophilia. Nihon Koeiky Gakkai Zasshi. 2000;38(12):397–42.
13. Michel J, Courthialac C, Andre M, Lhoste A, Aumaitre O. Quid? Pneumothorax complicating Wegener disease with rupture of pleura of cavitary nodule. J Radiol. 2001;82(1):73–5.
14. Bulbul Y, Oztu T, Oztuna F. Wegener’s granulomatosis with parotid gland involvement and pneumothorac. Med Princ Pract. 2003;12(2):133–7.
15. Imamoglu M, Bahadir O, Reis A. Parotid gland involvement as an initial presentation of Wegener’s granulomatosis. Otologynol Head Neck Surg. 2003;129(4):451–3.
16. Shimizu T, Ohara T, Ito S, Nakano M, Tsutsui N, Sato T, Suzuki E, Gelyo F. A case of Wegener’s granulomatosis complicated with seropneumothorax. Mod Rheumatol. 2003;13(2):181–4.
17. Delevaux I, Khalaf M, Andre M, Michel JL, Piette JC, Aumaitre O. Spontaneous pneumothorax in Wegener granulomatosis. Chest. 2005;128(4):3074–5.
18. Ates A, Karaalan Y, Yildiz G, Gunsen O, Han S. A case of Wegener’s granulomatosis complicated with hydropneumothorax. J Clin Rheumatol. 2006;12(5):264–5.
19. Storelli E, Casali C, Natali P, Rossi G, Morandi U. Unusual pathogenesis of spontaneous pneumothorax secondary to Wegener’s granulomatosis. Ann Thorac Surg. 2007;84(1):288–90.
20. Belhassen-Garcia M, Velasco-Tirado V, Alvina-Suarez L, Carpio-Perez A, Lledias JP, Novoa N, Iglesias-Gomez A, Cordero-Sanchez M. Spontaneous pneumothorax in Wegener’s granulomatosis: case report and literature review. Semin Arthritis Rheum. 2011;41(4):455–60.
21. Kahraman H, Inci MF, Tokur M, Cetin GY. Spontaneous pneumothorax in a patient with granulomatosis with polyangiitis. BMJ Case Rep. 2012;2012:
22. Ksalka J, Bajan-Socha S, Zuga J, Ignacak M, Zuk J, Sokolowska B, Musial J. Granulomatosis with polyangiitis (Wegener’s granulomatosis) with hard palate and bronchial perforations treated with rituximab - a case report. Pneumonol Alergol Pol. 2014;82(2):454–7.
23. Perio B, Dhir V, Singh PK, Gowda KK, Sharma A. Granulomatosis with polyangiitis and severe respiratory involvement. J Emerg Med. 2014;47(3):79–81.
24. Shi XH, Zhang YF, Lu YW. Successful treatment of granulomatosis with polyangiitis with hydropneumothorax using corticosteroids and immunosuppressant. Exp Ther Med. 2017;13(6):3586–90.
25. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, Calabrese LH, Fries JF, Lie JT, Lightfoot RW Jr, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. 1990;33(8):1101–7.
26. Ananthakrishnan L, Sharma N, Kanne JP. Wegener’s granulomatosis in the chest: high-resolution CT findings. AJR Am J Roentgenol. 2009;192(3):676–82.
27. Comarmond C, Cacoub P. Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. Autoimnun Rev. 2014;13(11):121–5.